At our 2024 Investor Day, we unveiled our 2030 Strategy to drive growth, profitability, and shareholder returns. ResMed disclosed a new five-year financial outlook that reflects ResMed's plans to accelerate product and technology innovation, operational excellence, commercial execution, and financial strength. Driven by the new strategy, in 2030, ResMed expects to help more than 500 million people worldwide to achieve their full health potential.

Speaker Bios Agenda Presentation

Speakers & Agenda

Schedule


1:00 PM ET
Welcome and Opening Remarks
Amy Wakeham, Chief Investor Relations Officer

Executive Presentations: ResMed 2030 Strategy
Mick Farrell, Chairman & Chief Executive Officer
Hemanth Reddy, Chief Strategy Officer
Justin Leong, Chief Product Officer
Bobby Ghoshal, Chief Commercial Officer, Residential Care Software

Q&A Session
ResMed Executive Team
2:50 PM ET
BREAK
3:00 PM ET Panel: Executive Discussion - Commercial Execution
Mike Fliss, Chief Revenue Officer
Katrin Pucknat, Chief Marketing Officer
Carlos Nunez, M.D., Chief Medical Officer
Moderated by: Mark Hayes, Breakwater Strategy

Financial Enablement & Growth Drivers
Brett Sandercock, Chief Financial Officer

Q&A Session
ResMed Executive Team

Panel: Medical Science & Sleep Apnea
Moderated by: Carlos Nunez, M.D., Chief Medical Officer

Closing Remarks
Mick Farrell, Chairman & Chief Executive Officer